MX2023004671A - Metodos para mejorar la funcion renal con una combinacion de un inhibidor del bromodominio y dominio extraterminal (bet) y un inhibidor del transporte de la glucosa dependiente del sodio 2. - Google Patents
Metodos para mejorar la funcion renal con una combinacion de un inhibidor del bromodominio y dominio extraterminal (bet) y un inhibidor del transporte de la glucosa dependiente del sodio 2.Info
- Publication number
- MX2023004671A MX2023004671A MX2023004671A MX2023004671A MX2023004671A MX 2023004671 A MX2023004671 A MX 2023004671A MX 2023004671 A MX2023004671 A MX 2023004671A MX 2023004671 A MX2023004671 A MX 2023004671A MX 2023004671 A MX2023004671 A MX 2023004671A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- methods
- combination
- glucose transport
- renal function
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 229940125763 bromodomain inhibitor Drugs 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 230000006377 glucose transport Effects 0.000 title 1
- 230000003907 kidney function Effects 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 abstract 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000024924 glomerular filtration Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107853P | 2020-10-30 | 2020-10-30 | |
| PCT/IB2021/060043 WO2022091028A1 (en) | 2020-10-30 | 2021-10-29 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004671A true MX2023004671A (es) | 2023-05-19 |
Family
ID=81382005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004671A MX2023004671A (es) | 2020-10-30 | 2021-10-29 | Metodos para mejorar la funcion renal con una combinacion de un inhibidor del bromodominio y dominio extraterminal (bet) y un inhibidor del transporte de la glucosa dependiente del sodio 2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230381178A1 (https=) |
| EP (1) | EP4236955A4 (https=) |
| JP (1) | JP2023547475A (https=) |
| KR (1) | KR20230098275A (https=) |
| CN (1) | CN116390721A (https=) |
| AU (1) | AU2021368618B2 (https=) |
| CA (1) | CA3197706A1 (https=) |
| IL (1) | IL301831A (https=) |
| MX (1) | MX2023004671A (https=) |
| TW (1) | TW202233194A (https=) |
| WO (1) | WO2022091028A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4678242A3 (en) * | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| AU2015210898A1 (en) * | 2014-01-31 | 2016-07-28 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| US10111885B2 (en) * | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
-
2021
- 2021-10-29 CA CA3197706A patent/CA3197706A1/en active Pending
- 2021-10-29 WO PCT/IB2021/060043 patent/WO2022091028A1/en not_active Ceased
- 2021-10-29 US US18/032,450 patent/US20230381178A1/en active Pending
- 2021-10-29 JP JP2023526313A patent/JP2023547475A/ja active Pending
- 2021-10-29 AU AU2021368618A patent/AU2021368618B2/en active Active
- 2021-10-29 MX MX2023004671A patent/MX2023004671A/es unknown
- 2021-10-29 EP EP21885492.5A patent/EP4236955A4/en active Pending
- 2021-10-29 CN CN202180072395.4A patent/CN116390721A/zh active Pending
- 2021-10-29 TW TW110140217A patent/TW202233194A/zh unknown
- 2021-10-29 IL IL301831A patent/IL301831A/en unknown
- 2021-10-29 KR KR1020237018039A patent/KR20230098275A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230098275A (ko) | 2023-07-03 |
| WO2022091028A1 (en) | 2022-05-05 |
| CA3197706A1 (en) | 2022-05-05 |
| EP4236955A4 (en) | 2024-08-07 |
| TW202233194A (zh) | 2022-09-01 |
| AU2021368618A1 (en) | 2023-05-04 |
| AU2021368618A9 (en) | 2024-09-05 |
| AU2021368618B2 (en) | 2025-02-27 |
| IL301831A (en) | 2023-06-01 |
| US20230381178A1 (en) | 2023-11-30 |
| EP4236955A1 (en) | 2023-09-06 |
| JP2023547475A (ja) | 2023-11-10 |
| CN116390721A (zh) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| EP0864327A1 (de) | Verwendung von Pyrimidinderivaten zur Prävention von Krebs | |
| EA201001772A1 (ru) | Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей | |
| BR112021022216A2 (pt) | Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado | |
| WO2022076831A3 (en) | Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer | |
| UA94719C2 (ru) | Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2024007335A (es) | Inhibidores de aldosterona sintasa para tratar la enfermedad renal cronica. | |
| EP1177791A3 (en) | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CR20210616A (es) | Formas de sales cristalinas de un inhibidor de cinasas | |
| IL277088B1 (en) | Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury | |
| MX2023004671A (es) | Metodos para mejorar la funcion renal con una combinacion de un inhibidor del bromodominio y dominio extraterminal (bet) y un inhibidor del transporte de la glucosa dependiente del sodio 2. | |
| WO2007022408A3 (en) | Combination methods of saha and targretin for treating cancer | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| MX2023000382A (es) | Inmunomoduladores heterocíclicos. | |
| MX2022005029A (es) | Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. | |
| EP4578499A3 (en) | Resmetirom for reducing liver volume | |
| WO2022133098A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| WO2022072645A3 (en) | Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer | |
| WO2022023447A3 (en) | Fused bicyclic raf inhibitors and methods for use thereof | |
| MX2022011238A (es) | Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. | |
| EA201270347A1 (ru) | Производные апогоссиполона в качестве противоопухолевых агентов |